**INTRA** 

$\neg$								
	I.1. Consignor				I.2. IMSOC reference I.2.a. Local reference			ence
	Name						I.3. Central Comp	petent Authority
	Address							
	Country ISO Code					I.4. Local Compe	tent Authority	
u	I.5. Consignee				I.6. Operator conducting	g assembly op	perations indepen	dently of an
of consignment	Name				establishment			
3	Address				Name			
ĭ	Country		ISO Co	de	Address Approval			
51					Number			
ı					Country		ISO Code	
	I.7. Country of orig	σin		ISO Code	I.9. Country of destinati	nn		ISO Code
	in country of only	5111			is country of destinati	011		
<u>1</u>	I.8. Region of origin Code				I.10. Region of destinati	on		Code
Part I: Description								
al E	I.11. Place of dispa	atch			I.12. Place of destination	1		
::	Name				Name			
11	Address Approval				Address			
ية الت	Number				Approval Number			
	Country		ISO Co	de	Country		ISO Code	
	I.13. Place of loadi	ng			I.14. Date and time of departure			
	Name	iig			1.14. Date and time of ut	parture		
	Address							
	Approval							
	Number		ISO Co	do				
	Country		150 00	ue				
	I.15. Means of Tra	nsport	1		I.16. Transporter			
	Mode	International transport	Identificati	on	Name			
		document			Address			
					Approval Number			
					Country		ISO Code	
					I.17. Accompanying doc	uments		
					Document Type Accompanying docume	·n+		
					reference			
				Date of Issue Country Place of issue				
	I.18. Transport co	nditions			_			
	Chilled $\square$	Chilled Ambient			Frozen 🗆			
	I.19. Container No	/ Seal No						
	I.20. Certified as							
	Germinal product	s 🗆						
	Oct. manua producto 🗀							
	I.21. For transit through a third country							
	Third country				ISO Code			
	Exit point				BCP code			
	Entry point				BCP code			
	I.22. For transit through Member State(s)				I.23. For export			
	Member State		ISO	Code	Third country		ISO Code	
					Exit point		BCP code	
	I.24. Estimated jou	24. Estimated journey time			I.25. Journey Log			
	I.26. Total number	r of packages		I.27. Total quantity		I.28. Total g	ross weight	
	I.30. Description o	f consignment						
	1. 05 PRODUCTS O	F ANIMAL ORIGIN	, NOT ELSE	WHERE SPECIFIED OR IN	ICLUDED			
	_		ere specified	or included; dead anim	als of Chapter   1   or 3, unfi	t for human o	consumption	
	<b>051199</b> Other							
	05119985 (	Other						

en 1/5

	- 1	#1. Commodity	Identification Number	Quantity	Nature of commodity	Identification Mark	
		Species	Package count	Date of collection / production	Plant / Establishment / Centre	Type	
	ŀ						
١.	_						
1	<u> </u>						
2	≝						
֡֝֟֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֡֓֓֓֓֡֡֡֓֓֡֡֡֓֓֡֡֡֓֓֡֡	<b>∄</b>						
1.5	20						
5	<b>=</b>						
5	3						
٦	3						
5	Ξl						
1.5	31						
1.	4						
3	31						
0	Š						
	۱						
Dart I: Description of consignment							
[	51						
مُ ا	7						
L	╛						
	7						
	- 1						

en 2/5

## 2024/1044~(2021/403)~Model~EQUI-OOCYTES-EMB-B-INTRA

_	NION		2024/1044 (2021/403) Model EQUI-OOC1 IE3-EMB-B-INTRA				
	II. Health info	rmation					
	I, the unde	rsigned offi	icial veterinarian, hereby certify that:				
	(1) o either	[II.1. the □ [in vivo derived embryos] (1) □ [in vivo derived ova] (1) described in Part I were collected, processed and stored by an embryo collection team (2) approved and supervised in accordance with Chapter I(III)(1) of Annex D to Directive 92/65/EEC (3);]					
rari III cerillicanon	(1) ∘ or	[II.1.	the $\square$ [in vitro produced embryos] (1) $\square$ [micromanipulated embryos] (1) described in Part I were produced, processed and stored by an embryo production team (2), approved and supervised in accordance with Chapter I(III) (1) and (2) of Annex D to Directive 92/65/EEC;]				
I Cer	(1) o either	[II.2.	the in vivo derived embryos described in Part I meet the requirements of Chapter III(II)(1) of Annex D to Directive 92/65/EEC;]				
rarıı	(1) ∘ or	[II.2.	the in vivo derived ova described in Part I meet the requirements of Chapter III(II)(2) of Annex D to Directive 92/65/EEC;]				
	(1) ∘ or	[II.2.	the in vitro produced embryos described in Part I meet the requirements of Chapter III(II)(3) of Annex D to Directive 92/65/EEC;]				
	(1) ∘ or	[II.2.	the micromanipulated embryos described in Part I meet the requirements of Chapter III(II)(4) of Annex D to Directive 92/65/EEC;]				
	II.3.	the □ [ov	va] (1) □ [embryos] (1) described in Part I come from donor mares which:				
	II.3.1.	which only	n holdings fulfilling the conditions laid down in Article 4(5) of Directive 2009/156/EC (4) onto y equidae satisfying the conditions laid down in Articles 4 and 5 or Articles 12 to 16 of 2009/156/EC were admitted;				
	II.3.2.	meet the r	equirements of Chapter IV(4) of Annex D to Directive 92/65/EEC;				
	II.3.3.	the ova or	used for natural breeding during a period of at least 30 days prior to the date of collection of embryos and between the date of the first sample referred to in points II.3.4.1 and II.3.4.2 and f the collection of the ova or embryos;				
	II.3.4.	Diagnostic recognised	vent the tests, which meet at least the requirements of the relevant Chapter of the Manual of stic Tests and Vaccines for Terrestrial Animals of the OIE, carried out in a laboratory which is ised by the competent authority and has the tests referred to hereinafter included in its tation in accordance with Article 12 of Regulation (EC) No 882/2004 (5), as follows:				
	II.3.4.1.	enzyme-lin taken on period refe	infectious anaemia (EIA), an agar-gel immuno-diffusion test (AGID or Coggins test) or an aked immunosorbent assay (ELISA) with a negative result carried out on a blood sample (6), being not less than 14 days following the date of commencement of the erred to in point II.3.3 and not more than 90 days prior to the date of the collection of the ovais intended for trade;				
	II.3.4.2.	least two s	ious equine metritis (CEM), an agent identification test carried out with a negative result on at pecimens (swabs) taken during the period referred to in point II.3.3 from at least the mucosal f the clitoral sinuses of the donor mare;				
	(1) □ either	[II.3.4.2.1.	on two occasions with an interval of not less than 7 days on  (6), in the case of isolation of Taylorella equigenitalis after cultivation under microaerophilic conditions for a period of at least 7 days, set up within the 24 hour period after taking the specimens from the donor animal, or the 48 hour period where the specimens are kept cool during transport;]				
	(1) □ and/or	[II.3.4.2.2.	on one occasion on (6), in the case of the detection of genome of Taylorella equigenitalis by a polymerase chain reaction (PCR) or real-time PCR test, carried out within the 48 hour period after taking the specimens from the donor animal.]				
	treatment)	or 21 days	to in points II.3.4.2.1 and II.3.4.2.2 were in no case taken earlier than 7 days (systemic (local treatment) after antimicrobial treatment of the donor mare and were placed in the charcoal, such as Amies medium, before dispatch to the laboratory;				
	(1) o either	[II.4.	the embryos described in Part I were conceived as a result of artificial insemination of the donor mares with semen which was collected, processed, stored and transported under conditions which comply with the requirements of Chapters I(I), II(I) and III(I) of Annex D to Directive 92/65/EEC;]				
	(1) ∘ or	[II.4.	the embryos described in Part I were conceived as a result of in vitro fertilisation of ova complying with the conditions set out in point 2 of Chapter III(II) of Annex D to Directive				
	L						

**en** 3/5

## 2024/1044 (2021/403) Model EQUI-OOCYTES-EMB-B-INTRA

	II. Health info	rmation								
fication										
				collected, processed, stored and transported under requirements of Chapters I(I), II(I) and III(I) of Annex D to						
	(1) or	[II.4.	the ova have not been in contact v	vith semen of the	e equine spec	ies;]				
	II.5.	the $\square$ [ov	a] (1) $\square$ [embryos] (1) described	in Part I:						
	II.5.1. were sent to the place of loading in a sealed container in accordance with point 6 of Chapter III(II) of Annex D to Directive 92/65/EEC and bearing the number detailed in box I.19;									
erti	II.5.2.	I.5.2. are dispatched:								
Part II: Certification	(1) o either									
	(1) ∘ or	[by an $\square$ [embryo collection team] (1) $\square$ [embryo production team] (1) or from a zone subject to movement restrictions affecting equine animals and established for from movement restrictions have been granted, and:								
	(1)	☐ [they co	mply with the requirements set ou	t in	(8);]]					
	(1)	$\square$ [and in	particular, they are (	9).]]						
	Notes									
	In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland/Northern Ireland in conjunction with Annex 2 to that Protocol, references to the Union in this animal health certificate include the United Kingdom in respect of Northern Ireland.									
	This animal health certificate shall be completed in accordance with the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.									
	Part I:  Box Place of dispatch shall correspond to the embryo collection team or embryo production team of ova/embryos collection/production.  I.11:									
	Box reference I.12:	Place of destination shall correspond to the embryo collection team, embryo production team or to the holding of ova/embryos destination.								
	Box reference I.19:	eference								
	Box reference I.26:	eference								
	Box reference I.30:		specify if: in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or nanipulated embryos.							
	Donor identity shall correspond to the official identification of the animal.  Date of collection shall be indicated in the following format: dd/mm/yyyy.									
	Part II:			-	,,,,					
	(1)	Delete if no	not applicable.							
	(2)	Only embr	yo collection or production teams a with Article 11(4) of Directive 92/0		competent au	thority and listed in				
	(3)	OJ L 268, 1	4.9.1992, p. 54.							
	(4)	OJ L 192, 2	3.7.2010, p. 1.							

en 4/5

## 2024/1044 (2021/403) Model EQUI-OOCYTES-EMB-B-INTRA

	II Hoolth inf	rmation						
	II. Health info	i illativit						
	(5)	011 405 00 40004						
	(5)	OJ L 165, 30.4.2004, p. 1.						
	(6)	Insert date.						
	(7)	Insert the name of the disease(s).						
	(8)	Insert the specific reference to the article(s), ti	tle, and number of the releva	nt legal act(s) adopted by the				
uc	(0)	Commission providing for those requirements						
atic	(9)	Insert the specific attestation(s) provided for i		at legal act(s) adopted by the				
fic		Commission, as referred to in Article 159(2), p						
Certification		European Parliament and of the Council.						
		icer/Official veterinarian						
Ξ	Name (in capi		Qualification and title					
	Date of declaration Stamp		Signature					
Ä	otamp							

**en 5** / 5